Identification of novel vaccine candidates against multidrug-resistant Acinetobacter baumannii

PLoS One. 2013 Oct 8;8(10):e77631. doi: 10.1371/journal.pone.0077631. eCollection 2013.


Acinetobacter baumannii is an emerging opportunistic bacterium associated with nosocomial infections in intensive care units. The alarming increase in infections caused by A. baumannii is strongly associated with enhanced resistance to antibiotics, in particular carbapenems. This, together with the lack of a licensed vaccine, has translated into significant economic, logistic and health impacts to health care facilities. In this study, we combined reverse vaccinology and proteomics to identify surface-exposed and secreted antigens from A. baumannii. Using in silico prediction tools and comparative genome analysis in combination with in vitro proteomic approaches, we identified 42 antigens that could be used as potential vaccine targets. Considering the paucity of effective antibiotics available to treat multidrug-resistant A. baumannii infections, these vaccine targets may serve as a framework for the development of a broadly protective multi-component vaccine, an outcome that would have a major impact on the burden of A. baumannii infections in intensive care units across the globe.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter Infections / immunology
  • Acinetobacter Infections / microbiology*
  • Acinetobacter Infections / prevention & control*
  • Acinetobacter baumannii / genetics
  • Acinetobacter baumannii / immunology*
  • Antigens, Bacterial / analysis
  • Antigens, Bacterial / immunology
  • Bacterial Outer Membrane Proteins / analysis
  • Bacterial Outer Membrane Proteins / immunology
  • Bacterial Vaccines / analysis
  • Bacterial Vaccines / immunology*
  • Computer Simulation
  • Drug Resistance, Multiple, Bacterial
  • Genome, Bacterial
  • Humans
  • Proteomics


  • Antigens, Bacterial
  • Bacterial Outer Membrane Proteins
  • Bacterial Vaccines

Grants and funding

This work was supported by grants from the Australian National Health and Medical Research Council, The University of Queensland, the Royal Brisbane and Women’s Hospital, and the Royal Brisbane and Women’s Hospital Foundation. MAS is supported by an Australian Research Council (ARC) Future Fellowship (FT100100662). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.